Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03433053 · ClinicalTrials.gov registry record · NA
Developing and Examining Evidenced-Based HIV Testing Messages
A NA study of HIV/AIDS, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 141
- Enrollment target
- 1
- Study location
NCT03433053: Completed NA study of HIV/AIDS, sponsored by Virginia Commonwealth University.
NCT03433053 is a NA study of HIV/AIDS that has completed, run by Virginia Commonwealth University. The registered enrollment target is 141 participants, below the 33,178-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03433053, a NA study of HIV/AIDS, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 141 participants
- Enrollment target
- 1
- Study location
Study Summary
The goals of this study are to: 1. Develop a HIV test message tailored for African American women. A generic non-tailored message will be developed as well for comparison. A third group will be included that will not be exposed to any message at all. 2. Test the effectiveness of both messages on reported future intentions to get tested for HIV and HIV test behavior at 3 month follow up.
Primary Outcome
Difference in future HIV test intentions between the tailored message group and the control group as measured by a follow up questionnaire, with higher scores indicating greater intention to be tested for HIV
Conditions Studied
Interventions
- BEHAVIORAL Control
- BEHAVIORAL HIV Testing Message Intervention
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2018-10-24 |
| Est. Completion | 2019-06-24 |
| Phase | NA |
What the finished NCT03433053 record still lists
NCT03433053 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 33,178-participant average among 61 other HIV/AIDS trials with a reported enrollment target (100% lower).
The record links to 1 condition, with HIV/AIDS appearing as the primary indexed condition, and to 2 interventions - of which Control is the first listed.
NCT03433053 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT03433053 about?
NCT03433053 is a clinical study titled "Developing and Examining Evidenced-Based HIV Testing Messages". The goals of this study are to: 1. Develop a HIV test message tailored for African American women. A generic non-tailored message will be developed as well for comparison. A third group will be included that will not be exposed to any message at all. 2. Test the effectiveness of both messages on re...
What is the current status of trial NCT03433053?
This trial is currently completed. It is a NA study. The enrollment target is 141 participants. The study started on 2018-10-24. Estimated completion is 2019-06-24.
What conditions does trial NCT03433053 study?
This clinical trial studies the following conditions: HIV/AIDS.
What interventions are being tested in trial NCT03433053?
The interventions under investigation include: Control (BEHAVIORAL), HIV Testing Message Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT03433053?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03433053 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV/AIDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03433053's enrollment target sits among peer trials
141 30th of 61 higher than 31 of 61 other HIV/AIDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV/AIDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
LinkPositively+ A Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected by Mental Health and Violence
RECRUITING · NA
-
MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM
RECRUITING · NA
-
MyPEEPS LITE Trial
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Improving the Organizational Social Context to Address Structural Racism and Discrimination
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
- NCT05814146 · 141 participants · NA
Trial of Variable Dialysate Bicarbonate
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI